← Eichor
Study identifier: NCT05390801 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Congenital Aniridia Patient Questionnaire

Condition: Congenital Aniridia  ·  Sponsor: Assistance Publique - Hôpitaux de Paris

PhaseN/A
Planned participants100
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

Congenital aniridia is a pan-ocular genetic disease characterized by a partial or complete absence of the iris, hence its name. The prevalence ranges from 1 / 40,000 to 1 / 96,000 births, but it may be underestimated. This condition combines several types of eye damage and could associate systemic manifestations, with a variable phenotype and genotype. This study aims to identify eye and systemic manifestations in congenital aniridia and to determine the patients' knowledge of their own disease through a survey prepared by ophthalmologists from the Ophthalmology Department of Necker-Enfants Malades Hospital, reference center in France for this pathology. The patient fills it out only once.

This description comes directly from the study's public registry record.

Talk to the study team

Alejandra Daruich, MD, PhD  ·  1 44 38 19 69  ·  alejandra.daruich-matet@aphp.fr

Hélène Morel  ·  1 71 19 63 46  ·  helene.morel@aphp.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Hôpital Necker-Enfants MaladesParis, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05390801